Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging
Background Labeled antibodies are excellent imaging agents in oncology to non-invasively visualize cancer-related antigens expression levels. However, tumor tracer uptake (TTU) of specific antibodies in-vivo may be inferior to non-specific IgG in some cases. Objectives To explore factors affecting l...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-06-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1177/15353508241261473 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841562112291241984 |
|---|---|
| author | Linhan Zhang MD Lianmeng Zhao MS Xue Lin MD Sheng Zhao MD Wenbin Pan MS Dandan Wang MD Zhongqi Sun MD Jinping Li MD Zonghui Liang MD Rongjun Zhang MS Huijie Jiang MD |
| author_facet | Linhan Zhang MD Lianmeng Zhao MS Xue Lin MD Sheng Zhao MD Wenbin Pan MS Dandan Wang MD Zhongqi Sun MD Jinping Li MD Zonghui Liang MD Rongjun Zhang MS Huijie Jiang MD |
| author_sort | Linhan Zhang MD |
| collection | DOAJ |
| description | Background Labeled antibodies are excellent imaging agents in oncology to non-invasively visualize cancer-related antigens expression levels. However, tumor tracer uptake (TTU) of specific antibodies in-vivo may be inferior to non-specific IgG in some cases. Objectives To explore factors affecting labeled antibody visualization by PD-L1 specific and non-specific imaging of nude mouse tumors. Methods TTU was observed in RKO model on Cerenkov luminescence (CL) and near-infrared fluorescence (NIRF) imaging of radionuclide 131 I or NIRF dyes labeled Atezolizumab and IgG. A mixture of NIRF dyes labeled Atezolizumab and 131 I-labeled IgG was injected, and TTU was observed in the RKO and HCT8 model by NIRF/CL dual-modality in-situ imaging. TTU were observed by 131 I-labeled Atezolizumab and IgG in-vitro distribution. Results Labeled IgG concentrated more in tumors than Atezolizumab. NIRF/CL imaging in 24 to 168 h showed that TTU gradually decreased over time, which decreased more slowly on CL imaging compared to NIRF imaging. The distribution data in-vitro showed that TTU of 131 I-labeled IgG was higher than that of 131 I-labeled Atezolizumab at any time point. Conclusion Non-specific IgG may not be suitable as a control for Atezolizumab in comparing tumor PD-L1 expression in nude mice via labeled antibody optical imaging under certain circumstances. |
| format | Article |
| id | doaj-art-a4d9b4dd41f94961bf597b29750b6b17 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-a4d9b4dd41f94961bf597b29750b6b172025-01-03T01:06:53ZengSAGE PublishingMolecular Imaging1536-01212024-06-012310.1177/15353508241261473Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ ImagingLinhan Zhang MD0Lianmeng Zhao MS1Xue Lin MD2Sheng Zhao MD3Wenbin Pan MS4Dandan Wang MD5Zhongqi Sun MD6Jinping Li MD7Zonghui Liang MD8Rongjun Zhang MS9Huijie Jiang MD10 Department of Nuclear Medicine, , Harbin, China Ultrasound Department, , Harbin, China Department of Radiology, , Harbin, China Department of Radiology, , Harbin, China Department of Radiology, , Harbin, China Department of Radiology, , Harbin, China Department of Radiology, , Harbin, China Department of Radiology, , Harbin, China Department of Radiology, , Shanghai, China Jiangsu Institute of Nuclear Medicine, Wuxi, China Department of Radiology, , Harbin, ChinaBackground Labeled antibodies are excellent imaging agents in oncology to non-invasively visualize cancer-related antigens expression levels. However, tumor tracer uptake (TTU) of specific antibodies in-vivo may be inferior to non-specific IgG in some cases. Objectives To explore factors affecting labeled antibody visualization by PD-L1 specific and non-specific imaging of nude mouse tumors. Methods TTU was observed in RKO model on Cerenkov luminescence (CL) and near-infrared fluorescence (NIRF) imaging of radionuclide 131 I or NIRF dyes labeled Atezolizumab and IgG. A mixture of NIRF dyes labeled Atezolizumab and 131 I-labeled IgG was injected, and TTU was observed in the RKO and HCT8 model by NIRF/CL dual-modality in-situ imaging. TTU were observed by 131 I-labeled Atezolizumab and IgG in-vitro distribution. Results Labeled IgG concentrated more in tumors than Atezolizumab. NIRF/CL imaging in 24 to 168 h showed that TTU gradually decreased over time, which decreased more slowly on CL imaging compared to NIRF imaging. The distribution data in-vitro showed that TTU of 131 I-labeled IgG was higher than that of 131 I-labeled Atezolizumab at any time point. Conclusion Non-specific IgG may not be suitable as a control for Atezolizumab in comparing tumor PD-L1 expression in nude mice via labeled antibody optical imaging under certain circumstances.https://doi.org/10.1177/15353508241261473 |
| spellingShingle | Linhan Zhang MD Lianmeng Zhao MS Xue Lin MD Sheng Zhao MD Wenbin Pan MS Dandan Wang MD Zhongqi Sun MD Jinping Li MD Zonghui Liang MD Rongjun Zhang MS Huijie Jiang MD Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging Molecular Imaging |
| title | Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging |
| title_full | Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging |
| title_fullStr | Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging |
| title_full_unstemmed | Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging |
| title_short | Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging |
| title_sort | comparison of tumor non specific and pd l1 specific imaging by near infrared fluorescence cerenkov luminescence dual modality in situ imaging |
| url | https://doi.org/10.1177/15353508241261473 |
| work_keys_str_mv | AT linhanzhangmd comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT lianmengzhaoms comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT xuelinmd comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT shengzhaomd comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT wenbinpanms comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT dandanwangmd comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT zhongqisunmd comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT jinpinglimd comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT zonghuiliangmd comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT rongjunzhangms comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging AT huijiejiangmd comparisonoftumornonspecificandpdl1specificimagingbynearinfraredfluorescencecerenkovluminescencedualmodalityinsituimaging |